196 related articles for article (PubMed ID: 9649482)
1. Selective COX-2 inhibitors: are they safe for the stomach?
Yeomans ND; Cook GA; Giraud AS
Gastroenterology; 1998 Jul; 115(1):227-9. PubMed ID: 9649482
[No Abstract] [Full Text] [Related]
2. [Pathogenesis of NSAID-induced gastric mucosal damage--search for primary events and role of COX inhibition].
Takeuchi K; Tanaka A; Miyazawa T
Nihon Shokakibyo Gakkai Zasshi; 2002 Jul; 99(7):751-9. PubMed ID: 12170703
[No Abstract] [Full Text] [Related]
3. Selective cyclooxygenase-2 inhibitors as potential therapeutic agents for inflammatory diseases.
Chan CC; Rodger IW
Adv Exp Med Biol; 1997; 407():157-61. PubMed ID: 9321947
[No Abstract] [Full Text] [Related]
4. [NSAIDs caused gastric mucosal injury: with a special reference to COX-2].
Sakamoto C
J Nippon Med Sch; 2003 Feb; 70(1):5-11. PubMed ID: 12646969
[TBL] [Abstract][Full Text] [Related]
5. Cyclooxygenase 1 contributes to inflammatory responses in rats and mice: implications for gastrointestinal toxicity.
Wallace JL; Bak A; McKnight W; Asfaha S; Sharkey KA; MacNaughton WK
Gastroenterology; 1998 Jul; 115(1):101-9. PubMed ID: 9649464
[TBL] [Abstract][Full Text] [Related]
6. [COX-2 expression in gastric cancers].
Sakamoto C
Nihon Rinsho; 2001 Apr; 59 Suppl 4():598-603. PubMed ID: 11424449
[No Abstract] [Full Text] [Related]
7. The future of NSAID therapy: selective COX-2 inhibitors.
Vane JR; Botting RM
Int J Clin Pract; 2000; 54(1):7-9. PubMed ID: 10750251
[No Abstract] [Full Text] [Related]
8. Characterization of prostaglandin H synthase 2 deficient mice and implications for mechanisms of NSAID action.
Morham SG; Langenbach R; Mahler J; Smithies O
Adv Exp Med Biol; 1997; 407():131-8. PubMed ID: 9321943
[No Abstract] [Full Text] [Related]
9. The role of COX-1 and COX-2 in asthma pathogenesis and its significance in the use of selective inhibitors.
Szczeklik A; Sanak M
Clin Exp Allergy; 2002 Mar; 32(3):339-42. PubMed ID: 11940059
[No Abstract] [Full Text] [Related]
10. Pharmacology and clinical action of COX-2 selective NSAIDs.
Bovill JG
Adv Exp Med Biol; 2003; 523():201-14. PubMed ID: 15088852
[No Abstract] [Full Text] [Related]
11. The discovery and function of COX-2.
Needleman P; Isakson PC
J Rheumatol Suppl; 1997 Jul; 49():6-8. PubMed ID: 9249644
[No Abstract] [Full Text] [Related]
12. Introduction: mechanism of action of NSAIDs.
Vane JR
Br J Rheumatol; 1996 Apr; 35 Suppl 1():1-3. PubMed ID: 8630629
[No Abstract] [Full Text] [Related]
13. COX-2-Selective NSAIDs: new and improved?
Lichtenstein DR; Wolfe MM
JAMA; 2000 Sep; 284(10):1297-9. PubMed ID: 10980759
[No Abstract] [Full Text] [Related]
14. Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 2. 1,3,4- and 1,2,4-thiadiazole series.
Song Y; Connor DT; Sercel AD; Sorenson RJ; Doubleday R; Unangst PC; Roth BD; Beylin VG; Gilbertsen RB; Chan K; Schrier DJ; Guglietta A; Bornemeier DA; Dyer RD
J Med Chem; 1999 Apr; 42(7):1161-9. PubMed ID: 10197960
[TBL] [Abstract][Full Text] [Related]
15. Prime suspect.
Manuel J
Environ Health Perspect; 1997 Jan; 105(1):28-9. PubMed ID: 9074875
[No Abstract] [Full Text] [Related]
16. The promise of coxibs: how far have we progressed?
Schumacher HR
J Pain Symptom Manage; 2002 Apr; 23(4 Suppl):S1-4. PubMed ID: 11992742
[No Abstract] [Full Text] [Related]
17. COX-2: Where are we in 2003? - Specific cyclooxygenase-2 inhibitors and aspirin-exacerbated respiratory disease.
Crofford LJ
Arthritis Res Ther; 2003; 5(1):25-7. PubMed ID: 12716444
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 1. Thiazolone and oxazolone series.
Song Y; Connor DT; Doubleday R; Sorenson RJ; Sercel AD; Unangst PC; Roth BD; Gilbertsen RB; Chan K; Schrier DJ; Guglietta A; Bornemeier DA; Dyer RD
J Med Chem; 1999 Apr; 42(7):1151-60. PubMed ID: 10197959
[TBL] [Abstract][Full Text] [Related]
19. COX-2 inhibitors: background knowledge for clinical use. Summary.
Katori M
Inflamm Res; 1998 Oct; 47 Suppl 2():S117. PubMed ID: 9831334
[No Abstract] [Full Text] [Related]
20. [Significance of COX-2].
Tatsuguchi A; Sakamoto C
Nihon Rinsho; 2002 Feb; 60 Suppl 2():207-10. PubMed ID: 11979779
[No Abstract] [Full Text] [Related]
[Next] [New Search]
